ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1391

Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 0957

Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0865

Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1319

Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 0973

Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1181

Real-World Myositis Antibody Frequency and Patient Awareness

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1340

Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1018

Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 0879

Recommendations for a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0959

Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1082

Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1128

Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1309

Refractory RA Patients for Targeted Therapies in Real Life

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1172

Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].